Capsid News and Research

RSS

New images capture startlingly high SARS-CoV-2 viral loads

Now, a team of scientists from the University of North Carolina at Chapel Hill School of Medicine produced striking images in respiratory tract cultures of the infectious form of the SARS-CoV-2 produced by infected epithelial cells.

16 Sep 2020

SARS-CoV-2 Neucleocapside (N) protein is heavily glycosylated

However, the nucleocapsid (N) protein is also extremely abundant and, therefore, a useful target for both vaccine and diagnostic test development. A new study published on the preprint server bioRxiv in August 2020 reveals the structure of this protein, a valuable step in using it for these purposes.

30 Aug 2020

Advances in Virus Epigenetics

Growing evidence shows viruses exploit epigenetic processes to control their life cycles but epigentic regulation of viral infections is not fully understood.

From Chromatrap® - Porvair Sciences Ltd 25 Aug 2020

UD researchers gain new insights into hepatitis B virus' genetic blueprint

Researchers at the University of Delaware, using supercomputing resources and collaborating with scientists at Indiana University, have gained new understanding of the virus that causes hepatitis B and the "spiky ball" that encloses the virus's genetic blueprint.

13 Aug 2020

Engineered capsids for improved gene delivery to the retina and cornea

A rational design approach created novel variants of adeno-associated viral (AAV) capsids.

13 Aug 2020

Researchers discover new method to treat herpes viruses

Researchers at Lund University in Sweden have discovered a new method to treat human herpes viruses. The new broad-spectrum method targets physical properties in the genome of the virus rather than viral proteins, which have previously been targeted.

24 Jul 2020

Analysis of the SARS-CoV-2 proteome via visual tools

Now, a new study published on the preprint server bioRxiv* in July 2020 shows how this can be advanced at a greater speed by combining experimental results with homology models obtained by high-throughput pipelines. This will help produce new hypotheses that will show novel druggable targets for effective drug development.

21 Jul 2020

New insight into the SARS-CoV-2 infection process

Canadian researchers from the Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, have found that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be using a unique method to gain entry into the cells.

16 Jul 2020

Researchers uncover new mechanism for designing antiviral drugs for dengue virus

A multidisciplinary team from The University of Texas Medical Branch at Galveston has uncovered a new mechanism for designing antiviral drugs for dengue virus. The study is currently available in Proceedings of the National Academy of Sciences.

14 Jul 2020

Study identifies three novel broad-spectrum SARS-CoV-2 cell entry inhibitors

Researchers from the National Institutes of Health (NIH) and Cornell University in the U.S. just described several new inhibitors of human coronavirus spike proteins by screening a library of approved drugs with SARS-S and MERS-S pseudotyped particle entry assays. Their exciting findings are currently available on the bioRxiv preprint server.

13 Jul 2020

Striking CryoEM image of SARS-CoV-2

A new study by researchers from the UK and Germany and published on the preprint server bioRxiv in June 2020 reports the results of a detailed study of the S protein on the intact virus, using cryoelectron microscopy (cryoEM) and tomography. This could help understand the conformation of the S protein on the virion and how it interacts with neutralizing antibodies.

30 Jun 2020

Growth, adaptation and neutralization of SARS-CoV-2 with acute-phase serum

One recent study published on the preprint server bioRxiv in June 2020 reports the results of growing and characterizing the virus, as well as the development of neutralizing antibodies in the serum of acutely infected hospitalized patients with COVID-19.

22 Jun 2020

Research explores the biophysical behavior of SARS-CoV-2 nucleocapsid protein

In a groundbreaking paper currently available on the bioRxiv* preprint server, the researchers from the Washington University School of Medicine and Stony Brook University showed how nucleocapsid protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is dynamic, disordered and phase separates with RNA – informing, in turn, the discovery of drugs that disrupt viral packaging.

21 Jun 2020

Irradiation with UV light kills SARS-CoV-2

Researchers in Italy have found that it is possible to completely inactivate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using short-wavelength UV (UV-C) irradiation.

8 Jun 2020

A key player in hepatitis A virus infection discovered

How hepatitis A virus manages to enter liver cells called hepatocytes and initiate infection had remained a mystery for fifty years until now.

26 May 2020

Study evaluates the effectiveness of interferon beta 1b in COVID-19 pneumonia

As the world struggles to overcome the current COVID-19 pandemic with non-pharmacological interventions, in the absence of an effective drug or vaccine, existing immunomodulators are being repurposed. A new study published on the preprint server medRxiv* in May 2020 shows no clinical benefit to the use of one such drug, called interferon beta 1b (IFN beta1b).

22 May 2020

Researchers discover unique structure and function of rotavirus VP3 protein

After eluding researchers for more than 30 years, the VP3 protein of rotavirus has finally revealed its unique structure and function to a team led by scientists at Baylor College of Medicine.

17 Apr 2020

Wyatt Technology Pioneers Multi-CQA Method for Gene Vectors

Wyatt Technology, the world leader in instrumentation for absolute macromolecular and nanoparticle characterization, announces the release of a novel method suitable for determining multiple critical quality attributes of adeno-associated virus and similar small gene vectors, in a single chromatographic run.

From Waters | Wyatt Technology 8 Apr 2020

Researchers develop chemically modified phage capsid that “stifles” influenza viruses

A new approach brings the hope of new therapeutic options for suppressing seasonal influenza and avian flu: On the basis of an empty - and therefore non-infectious - shell of a phage virus, researchers from Berlin have developed a chemically modified phage capsid that "stifles" influenza viruses.

31 Mar 2020

High-throughput screening of AAV vector capsid libraries reveals unexpected insights

Researchers have used high-throughput screening of adeno-associated viral (AAV) vector capsid libraries to maximize the likelihood of obtaining AAV variants with desired properties.

18 Mar 2020